Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
Chandy C JohnRobert O OpokaTeresa S LathamHeather A HumeCatherine NabaggalaPhillip KasiryeChristopher M NdugwaAdam LaneRussell E WarePublished in: The New England journal of medicine (2020)
Among children with sickle cell anemia in sub-Saharan Africa, hydroxyurea with dose escalation had superior clinical efficacy to that of fixed-dose hydroxyurea, with equivalent safety. (Funded by the Doris Duke Charitable Foundation and the Cincinnati Children's Research Foundation; NOHARM MTD ClinicalTrials.gov number, NCT03128515.).